Biovie is trading at $1.68 (-18.54%) after its 203-patient Phase 2 ADDRESS-LC trial failed to achieve statistical significance on any endpoint in the overall population.
- Predefined high-severity subgroups showed significant improvements, but the broad primary analysis disappointed investors.
- The company plans to advance bezisterim into a Phase 3 confirmatory trial, though the negative topline result is driving today’s sharp decline.